SEC Acting Enforcement Director Marc P. Berger To Depart The Commission Date
12/01/2021
The Securities and Exchange Commission today announced that Marc P. Berger, Acting Director of the Division of Enforcement, will conclude his tenure at the agency this month. Mr. Berger joined the Commission as Director of the New York Regional Office in December 2017 and was named Deputy Director of the Division of Enforcement in August 2020.
Under Mr. Berger s leadership, Enforcement staff pursued significant cases across the entire spectrum of the securities industry, with a focus on impactful and timely actions that protected investors and promoted market integrity. Mr. Berger focused on enhancing the efficiency and effectiveness of the Enforcement Division as well as the Division of Examinations programs in New York, better positioning the staff in both Divisions to address emerging threats and pursue misconduct. Mr. Berger prioritized the promotion of diversity and inclusion across
FOR IMMEDIATE RELEASE Washington D.C., Jan. 12, 2021
The Securities and Exchange Commission today announced that Marc P. Berger, Acting Director of the Division of Enforcement, will conclude his tenure at the agency this month. Mr. Berger joined the Commission as Director of the New York Regional Office in December 2017 and was named Deputy Director of the Division of Enforcement in August 2020.
Under Mr. Berger s leadership, Enforcement staff pursued significant cases across the entire spectrum of the securities industry, with a focus on impactful and timely actions that protected investors and promoted market integrity. Mr. Berger focused on enhancing the efficiency and effectiveness of the Enforcement Division as well as the Division of Examinations programs in New York, better positioning the staff in both Divisions to address emerging threats and pursue misconduct. Mr. Berger prioritized the promotion of diversity and inclusion across the Enforcement Div
TMCnet News
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Decision Diagnostics Corp. and Encourages Investors with Losses of $100,000 to Contact the Firm
[December 28, 2020]
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Decision Diagnostics Corp. and Encourages Investors with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Decision Diagnostics Corp. ( Decision or the Company ) (OTC: DECN) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Decision claimed early in the year that it had a finger prick test that could dtect the novel coronavirus and return results in less than one minute. The SEC (News - Alert) filed a lawsuit aga
DECN to Announce Various Testing Results This Week for Its COVID-19 GenViro! Swift Kit albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.
(2)
The company and its CEO thank supporters and remain fully committed; company will also provide a series of GenViro! test results it has amassed demonstrating the technology s promise
LOS ANGELES, CA / ACCESSWIRE / December 21, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) www.decisiondiagnostics.co, a leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters through its subsidiary Pharma Tech Solutions, Inc., as well as the designer and manufacturer of the proposed GenViro! Covid-19 :10 test kits, today announced it is proceeding with final testing of the GenViro! Covid-19 Saliva Swift Kit and will continue in its efforts to bring this valuable technology to market. Initially, the company will be releasing a series of test results collected from its Korean partner, from the detailed XPRIZE sample testing and as it becomes available, from its US-based testing, all of which will be submitted to the FDA for EUA consi